Abrégé

A method of determining the geometry of interaction between a protein or nucleic acid and one or more chemical entities, the method comprising the steps of: (a) providing an experimentally obtained multi-dimensional spectrum for a sample comprising the protein or nucleic acid and the one or more chemical entities; (b) providing two or more structural hypotheses; (c) obtaining a computationally generated multi-dimensional spectrum of the same type as the experimentally obtained multi-dimensional spectrum for each of the two or more structural hypotheses; (d) determining which of the computationally generated multi-dimensional spectra best fits the experimentally obtained multi-dimensional spectrum; and (e) based on step (d), identifying the geometry of interaction between the protein or nucleic acid and one or more chemical entities.

Classes IPC  ?

• G16B 15/30 - Ciblage de médicament à l’aide de données structurelles; Prévision d’amarrage ou de liaison moléculaire
• G01N 21/35 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge
• G16B 40/10 - Traitement du signal, p.ex. de spectrométrie de masse ou de réaction en chaîne par polymérase

Abrégé

A method of determining an effect of a modified peptide is disclosed. The method comprises comparing a behavioural phenotype of an organism, the organism having ingested a cell culture, wherein cells in the cell culture are configured to produce a modified peptide, with a reference behavioural phenotype of organisms of the same species, and determining whether the peptide has an effect based on the difference between the behavioural phenotype and the reference behavioural phenotype.

Classes IPC  ?

• G06V 10/771 - Sélection de caractéristiques, p.ex. sélection des caractéristiques représentatives à partir d’un espace multidimensionnel de caractéristiques
• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
• G06V 20/69 - Objets microscopiques, p.ex. cellules biologiques ou pièces cellulaires

Abrégé

The present invention relates to RNA molecules, and particularly, although not exclusively, to methods for preparing RNA molecules, and to methods for translating RNA molecules into protein. The invention extends to improved methods for forming RNA by in vitro transcription, and to the resultant RNA molecules. Furthermore, the invention relates to novel methods for enhancing the expression and/or translation of RNA, i.e. protein expression, and to methods for improving the stability of an RNA molecule. The invention also involves reducing the activation of innate sensing, interferon generation and/or degradation of an RNA molecule in a host. The invention also incorporates the use of the RNA molecules in vaccines and other therapeutic pharmaceutical compositions, and their use in immunisation and therapy, such as RNAi, gene therapy, gene editing and protein replacement. In particular, the invention relates to locked nucleotides and locked nucleic acid (LNA)-RNA molecules, and the use or incorporation of such locked nucleotides and LNA-RNA molecules in any of the above applications.

Abrégé

An aspect of the disclosure provides a bone implant system for stimulating growth in bone tissue cells of a human or animal patient, the system comprising: a bone implant (530); and an apparatus configured to be carried by the bone implant, the apparatus comprising: an energy provider (512), comprising an electromagnetic coupler configured to obtain electromagnetic energy via an electromagnetic field from an energy source disposed outside a body of the patient, wherein the electromagnetic coupler is carried by an external surface of the bone implant system; and a stimulator (517) configured to provide, based on energy from the energy provider, at least one of electrical or mechanical stimulus to a bone into which the bone implant is implanted.

Classes IPC  ?

• A61F 2/28 - Os
• A61F 2/48 - Moyens d'actionnement ou de commande, p.ex. de l'extérieur du corps, commande de sphincters

Abrégé

The present invention relates to methods for the synthesis of peptides and related compounds supported on a solid polymeric resin. The inventive method provides synthetic schemes that permit the coupling of two or more peptide fragments attached to the same polymeric support, in a fashion that allows access to previously unobtainable structures, and provides a more convenient and higher-yielding approach to known peptides, including those of commercial significance.

Classes IPC  ?

• C07K 1/04 - Procédés généraux de préparation de peptides sur des supports
• C07K 1/06 - Procédés généraux de préparation de peptides utilisant des groupes protecteurs ou des agents d'activation
• C07K 1/107 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs

Abrégé

An aspect of the disclosure provides a surgical robot (10) for deployment in an internal body lumen of a human or animal subject, the robot comprising: an inflatable scaffold (12) having a collapsed state for delivery to a target site in the lumen and an inflated state in which the scaffold defines an open cavity (18), a manipulator (14) movable in the cavity for manipulating a medical device; and a soft actuator (16) operable by fluid pressure to move the manipulator (14) by applying force between the scaffold (12) and the manipulator, wherein the scaffold (12) is arranged around the soft actuator (16) to provide protection between the soft actuator and the body lumen.

Classes IPC  ?

• A61B 34/30 - Robots chirurgicaux
• A61B 34/00 - Chirurgie assistée par ordinateur; Manipulateurs ou robots spécialement adaptés à l’utilisation en chirurgie
• A61M 25/01 - Introduction, guidage, avance, mise en place ou maintien en position des cathéters
• A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux, p.ex. tourniquets

Abrégé

The present invention relates to bioproduction of dyes and dyed biomaterials, and in particular relates to cells and methods for producing indigoidine. The invention also provides a dyed cellulose material and methods for producing the same.

Classes IPC  ?

• C12N 9/06 - Oxydoréductases (1.), p.ex. luciférase agissant sur des composés contenant de l'azote comme donneurs (1.4, 1.5, 1.7)
• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p.ex. kinases (2.7)
• C12N 9/88 - Lyases (4.)
• C12N 9/00 - Enzymes, p.ex. ligases (6.); Proenzymes; Compositions les contenant; Procédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
• C12P 17/16 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle contenant plusieurs hétérocycles
• C12R 1/645 - Champignons

Abrégé

The present invention provides a method for predicting an outcome of pregnancy, particular for predicting the likelihood of ectopic pregnancy (EP) or viable intrauterine pregnancy (VIUP), and methods for determining appropriate protocols for subjects with a pregnancy of unknown location (PUL) based on such an outcome, comprising determining the expression level of one or more specific miRNA molecules that are differentially expressed in scenarios of EP or VIUP, extracted from a biological sample obtained from said subject and comparing to a control value. The present invention also provides biochips and kits for use in carrying out the methods of the invention.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

A carbon-capture device and related processes are disclosed. The devices include substrate surfaces having a textured surfaces and a liquid sorbent contacting the texture surface in either a Cassie-Baxter state, in the case of a texture omniphobic surface or a plurality of re-entrant features or a Wenzel state, in the case of a textured omniphilic surface. The liquid sorbent reversibly captures a chemical species, which can usefully be carbon dioxide. This reversible capture can be exploited to capture and sequester carbon or other chemical species of interest.

Classes IPC  ?

• B32B 15/08 - Produits stratifiés composés essentiellement de métal comprenant un métal comme seul composant ou comme composant principal d'une couche adjacente à une autre couche d'une substance spécifique de résine synthétique
• B01D 53/14 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
• B32B 3/26 - Produits stratifiés caractérisés essentiellement par le fait qu'une des couches comporte des discontinuités ou des rugosités externes ou internes, ou bien qu'une des couches est de forme générale non plane; Produits stratifiés caractérisés essentiellement par des particularismes de forme caractérisés par une couche comportant des cavités ou des vides internes
• B32B 27/20 - Produits stratifiés composés essentiellement de résine synthétique caractérisée par l'emploi d'additifs particuliers utilisant des charges, des pigments, des agents thixotropiques
• B32B 27/32 - Produits stratifiés composés essentiellement de résine synthétique comprenant des polyoléfines

Abrégé

The present invention provides compositions and methods for enhancing fluorescence from emitters that emit in the NIR-II and NIR-III. The compositions have particular use in both in vitro diagnostics, and in the live imaging of tissue during surgery, for example during removal of a tumour.

Classes IPC  ?

• A61K 49/00 - Préparations pour examen in vivo

Abrégé

Disclosed herein is a compound according to formula Ia: Also disclosed herein are a pharmaceutical composition comprising the compound as aforementioned, use of the compound as aforementioned, a method of treating one or both of a microbial and a fungal infection comprising the step of administering a pharmaceutically effective amount of the compound as aforementioned or the pharmaceutical composition as aforementioned, and an antimicrobial and/or antifungal detergent composition comprising the compound as aforementioned, and a surfactant.

Classes IPC  ?

• C08G 73/06 - Polycondensats possédant des hétérocycles contenant de l'azote dans la chaîne principale de la macromolécule; Polyhydrazides; Polyamide-acides ou précurseurs similaires de polyimides
• C08L 79/04 - Polycondensats possédant des hétérocycles contenant de l'azote dans la chaîne principale; Polyhydrazides; Polyamide-acides ou précurseurs similaires de polyimides
• A61K 31/787 - Polymères contenant de l'azote contenant des hétérocycles ayant l'azote comme hétéro-atome d'un cycle
• A61K 8/40 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant de l'azote
• A61P 31/04 - Agents antibactériens
• A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61Q 5/02 - Préparations pour le lavage des cheveux
• A01P 1/00 - Désinfectants; Composés antimicrobiens ou leurs mélanges
• A01P 3/00 - Fongicides
• A01N 43/54 - Diazines-1,3; Diazines-1,3 hydrogénées

Abrégé

A computer-implemented method of controlling operation of a water distribution network, WDN, comprising obtaining data pertaining to parameters of the WDN; comparing the data with a hydraulic model of the WDN; determining an error value based on the comparing the data with the hydraulic model; determining that the error value is below a threshold; using the data to obtain an updated hydraulic model; and using the updated hydraulic model to control one or more elements of the WDN.

Classes IPC  ?

• G05B 17/00 - Systèmes impliquant l'usage de modèles ou de simulateurs desdits systèmes
• G06Q 50/06 - Fourniture d'électricité, de gaz ou d'eau

Abrégé

The disclosure related to an interferometer comprising a first mirror array comprising a first mirror and a second mirror; and an adjustable beam-steering device. The beam steering device configured to receive a first beam and a second beam, split from a source beam; steer the first beam onto the first mirror of the first mirror array; and steer the second beam onto the second mirror of the first mirror array. The first mirror array is configured to reflect, by the first mirror, the first beam, and reflect, by the second mirror, the second beam, to combine the first beam and the second beam to generate an interference pattern.

Classes IPC  ?

• G01B 9/02001 - Interféromètres caractérisés par la commande ou la génération des propriétés intrinsèques du rayonnement
• G01B 9/02015 - Interféromètres caractérisés par la configuration du parcours du faisceau
• G01B 11/25 - Dispositions pour la mesure caractérisées par l'utilisation de techniques optiques pour mesurer des contours ou des courbes en projetant un motif, p.ex. des franges de moiré, sur l'objet
• G02B 26/08 - Dispositifs ou dispositions optiques pour la commande de la lumière utilisant des éléments optiques mobiles ou déformables pour commander la direction de la lumière

Abrégé

Small molecules have been the preferred modality for drug development and therapeutic interventions. This molecular format presents a number of advantages, e.g. long half-lives and cell permeability, making it possible to access a wide range of therapeutic targets. However, finding small molecules that engage “hard-to-drug” protein targets specifically and potently remains an arduous process, requiring experimental screening of extensive compound libraries to identify candidate leads. The search continues with further optimization of compound leads to meet the required potency and toxicity thresholds for clinical applications. Here, we propose a new computational workflow for high-throughput fragment-based screening and binding affinity prediction where we leverage the available protein-ligand complex structures using a state-of-the-art protein surface embedding framework (dMaSIF). We developed a tool capable of finding suitable ligands and fragments for a given protein pocket solely based on protein surface descriptors, that capture chemical and geometric features of the target pocket. The identified fragments can be further combined into novel ligands. Using the structural data, our ligand discovery pipeline learns the signatures of interactions between surface patches and small pharmacophores. On a query target pocket, the algorithm matches known target pockets and returns either potential ligands or identifies multiple ligand fragments in the binding site. Our binding affinity predictor is capable of predicting the affinity of a given protein-ligand pair, requiring only limited information about the ligand pose. This enables screening without the costly step of first docking candidate molecules. Our framework will facilitate the design of ligands based on the target's surface information. It may significantly reduce the experimental screening load and ultimately reveal novel chemical compounds for targeting challenging proteins.

Classes IPC  ?

• G16B 15/30 - Ciblage de médicament à l’aide de données structurelles; Prévision d’amarrage ou de liaison moléculaire
• G16B 40/20 - Analyse de données supervisée

Abrégé

22).

Classes IPC  ?

• C08J 11/16 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p.ex. dévulcanisation par traitement avec une substance inorganique
• B29B 17/04 - Désintégration des matières plastiques

Abrégé

An apparatus for extruding a material, the apparatus comprising: a block which includes two or more extrusion containers composed of heat resisting material, the containers being arranged to receive billets of the extruding material; a die set arranged downstream of the block including the two or more extrusion containers; and one or more rams, wherein the one or more rams are aligned with the axes of the extrusion containers and are arranged to push the billets of material through the extrusion containers into the die set; wherein the die set includes an upper die including two or more extrusion channels for extruding material from each of the extrusion containers, and a lower die incorporating a welding chamber, wherein two or more extruded billets from each of the extrusion channels are welded together and passed out through the exit of the die set.

Classes IPC  ?

• B21C 33/00 - Alimentation des presses d'extrusion en métal à extruder
• B21C 23/06 - Fabrication de tôles
• B21C 23/21 - Presses spécialement adaptées à l'extrusion du métal
• B21C 25/02 - Matrices
• B21C 27/00 - Conteneurs pour métaux à extruder

Abrégé

The present invention relates to isolated oligonucleotides for treating or preventing inflammation or muscle atrophy. In particular, the invention relates to isolated antisense oligonucleotides which bind to a lncRNA, wherein the lncRNA acts as a molecular sponge for a given miRNA, and wherein the binding of the oligonucleotide to the lncRNA increases the abundance and/or availability of said miRNA in a cell.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens

Abrégé

Disclosed herein are methods and systems of determining a magnetically induced voltage on a coil of a wireless power transmission device. The method comprises supplying DC input power to the wireless power transmission device. It further comprises monitoring a first variable associated with the wireless power transmission device, and monitoring a second variable associated with the wireless power transmission device, wherein at least one of the first and the second variable is derived from a switching waveform. It further comprises determining, based on at least one of the first variable, the second variable, and the relationship between the first variable and the second variable, the magnetically induced voltage on the coil of the wireless power transmission device.

Classes IPC  ?

• H02J 50/60 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique sensibles à la présence d’objets étrangers, p.ex. détection d'êtres vivants
• H02J 50/12 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique utilisant un couplage inductif du type couplage à résonance

Abrégé

The disclosure relates to a valve (20) for use with breathing assistance apparatus. The valve comprises: a valve body (25) defining first, second and third ports (21, 22, 23); a valve core (27) defining a ported chamber (40) rotatable about a valve axis (28) between: a first stable configuration in which the ported chamber provides fluid communication between the first port and the second port and isolates the third port from the first and second ports; and a second stable configuration in which the ported chamber provides fluid communication between the first port and the third port and isolates the second port from the first and third ports, wherein an outer surface (34) of the valve core is configured to engage with an inner surface (32) of the valve body to define a detent for resisting rotation of the valve core between the first stable configuration and the second stable configuration; and an actuator (30) configured to overcome the detent to rotate the valve core between the first and second stable configurations.

Classes IPC  ?

• A61M 16/20 - Valves spécialement adaptées aux dispositifs respiratoires médicaux
• F16K 11/083 - Soupapes ou clapets à voies multiples, p.ex. clapets mélangeurs; Raccords de tuyauteries comportant de tels clapets ou soupapes; Aménagement d'obturateurs et de voies d'écoulement spécialement conçu pour mélanger les fluides dont toutes les faces d'obturation se déplacent comme un tout comportant uniquement des robinets à boisseau à noix conique
• F16K 11/085 - Soupapes ou clapets à voies multiples, p.ex. clapets mélangeurs; Raccords de tuyauteries comportant de tels clapets ou soupapes; Aménagement d'obturateurs et de voies d'écoulement spécialement conçu pour mélanger les fluides dont toutes les faces d'obturation se déplacent comme un tout comportant uniquement des robinets à boisseau à noix cylindrique
• F16K 31/524 - Moyens mécaniques d'actionnement à manivelle, excentrique ou came à came
• F16K 31/56 - Moyens mécaniques d'actionnement sans position intermédiaire stable, p.ex. par à-coup
• F16K 31/60 - Poignées

Abrégé

An apparatus for generating random numbers, the apparatus comprising one or more bit stream generators, wherein each bit stream generator comprises: a memristor; a pulse generator configured to: generate a plurality of pulses; and apply the plurality of pulses through the memristor to generate an output comprising a plurality of output pulses; and a comparison means configured to: compare a first sample of the pulsed output with a second sample of the pulsed output; and output, based on the first comparison, information indicative of a randomly generated bit of a random bit stream.

Classes IPC  ?

• G06F 7/58 - Générateurs de nombres aléatoires ou pseudo-aléatoires

Abrégé

Systems and methods for ultrasound devices are presented. A system may comprise an ultrasound transducer having a terminal, a driver in electrical communication with the ultrasound transducer via the terminal, and a receiver in electrical communication with the ultrasound transducer via the terminal. The ultrasound transducer is configured to simultaneously transmit and receive a modulated signal and methods allowing for the simultaneous transmission and reception are used.

Classes IPC  ?

• G01S 7/52 - DÉTERMINATION DE LA DIRECTION PAR RADIO; RADIO-NAVIGATION; DÉTERMINATION DE LA DISTANCE OU DE LA VITESSE EN UTILISANT DES ONDES RADIO; LOCALISATION OU DÉTECTION DE LA PRÉSENCE EN UTILISANT LA RÉFLEXION OU LA RERADIATION D'ONDES RADIO; DISPOSITIONS ANALOGUES UTILISANT D'AUTRES ONDES - Détails des systèmes correspondant aux groupes , , de systèmes selon le groupe
• G01S 15/89 - Systèmes sonar, spécialement adaptés à des applications spécifiques pour la cartographie ou la représentation

Abrégé

This disclosure describes a novel “kick and kill” strategy as an effective cancer therapy for treating virus-associated cancers. In particular, this disclosure provides a method of reactivating a latent Epstein-Barr virus (EBV) in a cell infected with the EBV. Also provided are a method of eliciting or enhancing an immune response against an EBV-positive cancer cell in a subject infected with the EBV and a method of treating a subject having cancer associated with EBV infection.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 31/136 - Amines, p.ex. amantadine ayant des cycles aromatiques, p.ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p.ex. benzène-amine
• A61K 31/4406 - Pyridines non condensées; Leurs dérivés hydrogénés substituées uniquement en position 3, p.ex. zimeldine
• A61K 31/454 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pimozide, dompéridone
• A61K 31/473 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. acridines, phénantridines
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
• A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine liés à un système carbocyclique condensé, p.ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
• C07K 14/725 - Récepteurs de lymphocytes-T
• C07K 16/08 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus

Abrégé

The present invention relates to methods for the production of immune cells and immunomodulatory cells expressing a transgene of interest, using lentiviral vectors. The invention also relates to populations of cells produced by such methods and uses thereof.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• C12N 5/0786 - Monocytes; Macrophages
• C12N 15/86 - Vecteurs viraux

Abrégé

The invention relates media, compositions, medium supplements and a method of making same for high-yield culture of fastidious bacteria.

Abrégé

The invention relates to a sub-micron particle comprising a payload molecule and a lipid structure being surrounded by an outer layer comprising an amphiphilic copolymer. The invention extends to method of producing the sub-micron particle. The invention also encompasses pharmaceutical compositions and vaccines comprising the sub-micron particle and medical uses thereof.

Classes IPC  ?

• A61K 9/51 - Nanocapsules
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/145 - Orthomyxoviridae, p.ex. virus de l'influenza
• A61K 39/215 - Coronaviridae, p.ex. virus de la bronchite infectieuse aviaire
• A61P 37/04 - Immunostimulants

Abrégé

The present invention relates to biomaterials, in particular bacterial cellulose and provides means to prepare pigmented cellulose at acidic pH 5.8, wherein cellulose pellicles comprising tyrosinase (EC 1.14.18.1) are melanated using a development solution at pH 6 to 8.5 and comprises tyrosine, cysteine and/or cystine. Further, the invention relates to means of preparing spatially restricted pigmented cellulose using an optogenetic expression system wherein two polymerase or transcription factor domains are split and each linked to a light-inducible dimerization domain. The invention provides corresponding methods and components.

Classes IPC  ?

• C12P 19/04 - Polysaccharides, c. à d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
• C12N 1/20 - Bactéries; Leurs milieux de culture
• C12N 9/02 - Oxydoréductases (1.), p.ex. luciférase
• C12P 17/10 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'azote comme unique hétéro-atome du cycle

Abrégé

The invention relates to gene signatures. In particular, the invention relates methods and kits for diagnosing a subject having a disease, by simultaneously discriminating between multiple infectious and inflammatory diseases using a gene signature. The invention also relates to the use of a gene signature as a diagnostic or prognostic biomarker for diseases.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The invention relates to biomarkers, and to novel biological markers for diagnosing colorectal cancer. In particular, the invention relates to the use of these biomarkers as diagnostic and prognostic markers in assays for detecting colorectal cancer, and corresponding methods of detection. The invention also relates to methods of determining the efficacy of treating colorectal cancer with a therapeutic agent, and apparatus for carrying out the assays and methods. The assays are qualitative and/or quantitative, and are adaptable to large-scale screening and clinical trials.

Classes IPC  ?

• G01N 33/497 - Analyse physique de matériau biologique de matériau biologique gazeux, p.ex. de l'haleine

Abrégé

A method of manufacturing a fibre comprising a lined channel, using a draw apparatus, the method comprising: providing a preform, comprising a channel extending through the preform, to the draw apparatus; feeding a liner into the channel; heating a portion of the preform; and drawing the heated portion of the preform in order to form a fibre, wherein the liner is held within the channel of the fibre to provide a lined channel within the fibre.

Classes IPC  ?

• B29C 55/22 - Façonnage par étirage, p.ex. étirage à travers une matrice; Appareils à cet effet de tubes
• A61M 25/00 - Cathéters; Sondes creuses
• B29C 55/00 - Façonnage par étirage, p.ex. étirage à travers une matrice; Appareils à cet effet
• B29K 627/18 - PTFE, c.à d. polytétrafluoro-éthylène
• B29L 31/00 - Autres objets particuliers

Abrégé

The present invention relates to nucleic acid cassettes for gene therapy, particularly to promoter and promoter/enhancer combinations for improved expression of transgenes in a lung parenchyma‐specific/preferred manner. The invention further relates nucleic acid cassettes comprising said promoters and promoter/enhancer combinations, viral and non‐viral vectors comprising such nucleic acid cassettes, and the use of such nucleic acid cassettes and vectors to increase expression of therapeutic proteins by lung parenchyma cells.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

The present invention relates to an anti-CRISPR construct useful to counteract the spread of a gene-drive in an arthropod population. The invention is also concerned with a system comprising the anti-CRISPR construct and a crispr-based gene-drive construct, a method of producing a genetically modified arthropod, a genetically modified arthropod, and a method for counteracting a CRISPR-based gene-drive in an arthropod population.

Classes IPC  ?

• A01K 67/033 - NÉCESSITÉS COURANTES DE LA VIE ÉLEVAGE; CHASSE; PIÉGEAGE; PÊCHE ÉLEVAGE; AVICULTURE; APICULTURE; PISCICULTURE; PÊCHE; OBTENTION D'ANIMAUX, NON PRÉVUE AILLEURS; NOUVELLES RACES D'ANIMAUX Élevage ou obtention d'animaux, non prévus ailleurs; Nouvelles races d'animaux Élevage ou obtention d'invertébrés; Nouvelles races d'invertébrés
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

A device comprising a bendable fibre comprising a fibre axis, a thermally expandable material and a resistance wire extending longitudinally through the fibre spaced apart from the fibre axis; wherein, in use, electrical power applied to the resistance wire causes the temperature of the resistance wire to increase.

Classes IPC  ?

• D01D 5/24 - Formation des filaments, fils ou similaires à structure creuse; Ensembles de filage à cet effet
• B29C 55/22 - Façonnage par étirage, p.ex. étirage à travers une matrice; Appareils à cet effet de tubes
• B29L 23/00 - Objets tubulaires
• D01F 8/00 - Filaments, ou similaires, faits par l’homme, conjugués, c. à d. à plusieurs composants; Leur fabrication
• H05B 3/56 - Câbles chauffants

Abrégé

The invention is directed to a method for identifying a candidate anti-glioma drug that is a mitochondrial F1Fo ATP Synthase c-subunit leak channel opener, the method comprising: a. providing an admixture comprising: i. a candidate drug; ii. a submitochondrial vesicle (SMV) preparation; and iii. an H+ probe, wherein the H+ probe remains outside of the SMV(s); b. contacting the admixture with ATP; c. measuring a level of H+ outside of the SMV(s) via the H+ probe; d. comparing the level of H+ at step c) with a level of H+ in a control admixture lacking the candidate drug; and identifying the drug as a candidate anti-glioma drug that is a mitochondrial F1Fo ATP Synthase c-subunit leak channel opener, when the level of H+ is higher compared to the level of H+ in the control admixture; or identifying that the drug is not a candidate anti-glioma drug that is a mitochondrial F1Fo ATP Synthase c-subunit leak channel opener, when the level of H+ is the same or lower compared to the level of H+ in the control admixture.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
• A61K 31/075 - Ethers ou acétals
• A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
• A61K 31/423 - Oxazoles condensés avec des carbocycles
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/44 - Pyridines non condensées; Leurs dérivés hydrogénés
• A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
• A61P 35/00 - Agents anticancéreux
• G01N 21/64 - Fluorescence; Phosphorescence

Abrégé

Disclosed herein are methods and systems for determining optimal primer sets for a multiplex assay, each of the optimal primer sets intended to amplify one or more targets. The method comprises obtaining amplification data from a plurality of preparatory assays. The amplification data describes at least the amplification of a first target of the one or more targets by a first primer set in a first preparatory assay, the amplification of the first target amplified by a second primer set in a second preparatory assay, the amplification of a second target of the one or more targets by the first primer set in a third preparatory assay, and the amplification of the second target by the second primer set in a fourth preparatory assay. The method further comprises determining a plurality of similarity metrics, each similarity metric being indicative of a degree of similarity between the amplification data produced by one of the plurality of preparatory assays compared to another one of the preparatory assays. The method further comprises determining, based on the plurality of similarity metrics, the optimal primer sets for the multiplex assay.

Classes IPC  ?

• G16B 25/20 - Réaction en chaîne par polymérase; Conception d’amorces ou de sondes; Optimisation de la sonde
• G16B 40/10 - Traitement du signal, p.ex. de spectrométrie de masse ou de réaction en chaîne par polymérase

Abrégé

The present disclosure relates to a method and system for measuring electric field at a location in a volume of an electrolytic medium and a method and system for applying an electric field to a location in a volume of an electrolytic medium. An aspect of the disclosure provides a method of determining an electric field at a location in a volume of an electrolytic medium, the method comprising: applying, to the location, acoustic energy having a first frequency; sensing an electric field for the volume to obtain a sensed electric field signal; determining, based on the sensed electric field signal and based on a reference signal having the first frequency, the electric field at the location, the electric field at the location having a second frequency.

Classes IPC  ?

• A61B 5/05 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio
• A61B 5/24 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci
• A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
• A61N 1/40 - Application de champs électriques par couplage inductif ou capacitif
• G01R 29/14 - Mesure de la distribution du champ

Abrégé

An injection device comprising: a first barrel for containing a first fluid, and having a first plunger; a second barrel for containing a second fluid, and having a second plunger, the second barrel being arranged to one side of the first barrel; a flow converging chamber in fluid communication with the second barrel, for receiving, in use, a flow of the second fluid from the second barrel when the second plunger is advanced within the second barrel; a first inlet to the flow converging chamber, in communication with the first barrel, for receiving, in use, a flow of the first fluid from the first barrel when the first plunger is advanced within the first barrel, simultaneously with the advancement of the second plunger, and arranged to introduce the flow of the first fluid in a concentric manner within the flow of the second fluid, at a meeting point within the flow converging chamber, to produce a concentric flow of the first fluid within the second fluid; and an outlet of the flow converging chamber, for outwardly delivering the concentric flow of the first fluid within the second fluid. The first fluid may contain biological materials such as cells, and may for example comprise a hydrogel. The second fluid may comprise an aqueous fluid such as phosphate-buffered saline. Also provided is a method of delivering a concentric flow of a first fluid within a second fluid, using such an injection device.

Classes IPC  ?

• B01L 3/02 - Burettes; Pipettes

Abrégé

The present disclosure relates to a microfluidic device for discriminating between second cells, as a function of binding strength between first cells and the second cells, the device comprising: a microfluidic channel, a base of the channel comprising a substrate; wherein the channel is configured to receive first cells, for adhesion of the first cells to the substrate; receive second cells, for adhesion of the second cells to the first cells; and receive a fluid, for fluid flow over the second cells; and wherein a transverse cross-section of the channel is configured for application of a substantially uniform shear stress to the second cells that are adhered to the first cells in at least a central region of the channel as the fluid flows along the channel, to detach at least some of the second cells from the first cells, and to cause the detached second cells to flow towards a downstream end of the channel.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
• G01N 33/483 - Analyse physique de matériau biologique

Abrégé

The present invention relates to the use of ultrasound imaging techniques and computer implemented image processing methods for determining and assessing male infertility, as well as non-invasive diagnostic methods to identify and diagnose male infertility, such as hypogonadism (testosterone deficiency). Furthermore, the invention relates to methods of selecting male subjects for fertility treatment and methods for the treatment of these subjects. There is described a computer-implemented method for assessing testicular function in a male subject, the method comprising: receiving one or more ultrasound image collected using contrast-enhanced ultrasound (CEUS) and/or super-resolution ultrasound (SRUS); determining one or more testicular parameters from the one or more ultrasound images; comparing the one or more parameters to one or more threshold values of the one or more parameters; determining a difference between the one or more parameters and the one or more threshold values; and outputting an indication of testicular function based on the comparison of the one or more parameters with the one or more threshold values.

Classes IPC  ?

• A61B 8/08 - Détection de mouvements ou de changements organiques, p.ex. tumeurs, kystes, gonflements
• G03B 42/00 - Production d'enregistrements en utilisant d'autres ondes que des ondes optiques; Visualisation de ces enregistrements en utilisant des moyens optiques

Abrégé

The invention relates to phage vectors, and to novel phage vectors comprising transgenes, in particular conventional mammalian transgene cassettes. The invention extends to the use of such phage vectors as a research tool, and for the delivery of transgenes in a variety of gene therapy applications, DNA and/or peptide vaccine delivery and imaging techniques.

Classes IPC  ?

• C12N 15/86 - Vecteurs viraux
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

The present disclosure is related to processes for the manufacture of electrolyte-gated graphene field effect transistors comprising deposition of ink compositions comprising graphene to form conductive films comprising graphene and the use of said transistors as chemo- and bio-sensors.

Classes IPC  ?

• G01N 27/414 - Transistors à effet de champ sensibles aux ions ou chimiques, c. à d. ISFETS ou CHEMFETS

Abrégé

An antibody or antigen-binding fragment thereof is described which binds to the spike protein S2 domain of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome-related coronavirus (MERS-CoV) and/or severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). The antibodies can be used in the diagnosis and treatment of coronavirus infection. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions, diagnostic compositions, and kits. The invention also extends to methods of making and using the antibodies, for example in the diagnosis and therapy of coronavirus infections.

Classes IPC  ?

• A61K 39/42 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire viraux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

An apparatus for a diagnostic testing device, the diagnostic testing device comprising a plunger for delivering a fluid for use in a diagnostic test, the apparatus comprising: a wire-based muscle-like actuator; circuitry configured to heat, and cause a corresponding contraction of, the wire-based muscle-like actuator; and a lever mechanically coupled to the wire-based muscle-like actuator such that contraction of the wire-based muscle-like actuator actuates the lever from a first position to a second position for activating the plunger to deliver the fluid.

Classes IPC  ?

• F16K 31/00 - Moyens de fonctionnement; Dispositifs de retour à la position de repos
• B01L 3/02 - Burettes; Pipettes
• G05D 23/02 - Commande de la température sans source d'énergie auxiliaire avec un élément sensible se dilatant et se contractant en réponse aux variations de température

Abrégé

The present invention relates to chimeric antigen receptor (CAR)-T cells, and particularly, although not exclusively, to their use in immunotherapy, and for treating, preventing or ameliorating cancer, such as T-cell lymphomas, various microbial infections, such as HIV and TB, and also autoimmune disease. The invention is especially concerned with the use of CAR-engineered mucosal-associated invariant T (MAIT) cells, and to novel methods for stimulating, isolating, and expanding highly purified MAIT cells, which can then be engineered into such CAR-MAIT cells. The invention is also concerned with methods for expansion of MAIT cells in vitro.

Classes IPC  ?

• A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
• C12N 15/86 - Vecteurs viraux

Abrégé

The present invention relates to chimeric antigen receptor (CAR)-T cells, and particularly, although not exclusively, to anti-T-cell receptor (TCR) V-beta CARs, and to their use in immunotherapy, and for treating, preventing or ameliorating cancer, such as T-cell lymphomas, various microbial infections, such as HIV and TB, and also autoimmune disease. The invention is especially concerned with the use of CAR-engineered mucosal-associated invariant T (MAIT) cells, and to novel methods for stimulating, isolating and expanding highly purified MAIT cells, which can then be engineered into such CAR-MAIT cells. The invention extends to genetic constructs per se, and to their use in generating the CAR-MAIT cells, and to transduced CAR-MAIT cells per se. The invention also extends to various medical uses of the constructs and transduced CAR-MAIT cells, and to pharmaceutical compositions comprising these constructs and CAR-MAIT cells.

Classes IPC  ?

• A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

The invention relates to genetic constructs, and in particular to genetic constructs for use in population suppression, and pest control. The invention particularly relates to genetic constructs capable of disrupting a haplo-sufficient gene needed for survival or reproduction in an organism, wherein the genetic construct encodes a genomic editor that creates a dominant lethal or sterile mutation in a target gene of the organism. The invention is also concerned with methods of suppressing wild-type populations by use of the genetic constructs described herein.

Classes IPC  ?

• A01K 67/033 - NÉCESSITÉS COURANTES DE LA VIE ÉLEVAGE; CHASSE; PIÉGEAGE; PÊCHE ÉLEVAGE; AVICULTURE; APICULTURE; PISCICULTURE; PÊCHE; OBTENTION D'ANIMAUX, NON PRÉVUE AILLEURS; NOUVELLES RACES D'ANIMAUX Élevage ou obtention d'animaux, non prévus ailleurs; Nouvelles races d'animaux Élevage ou obtention d'invertébrés; Nouvelles races d'invertébrés
• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome

Abrégé

This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, for example in a method of treatment. There are also provided processes for producing compounds of the present invention and method of their use. In particular, the present invention relates to compounds of formula (I). This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, for example in a method of treatment. There are also provided processes for producing compounds of the present invention and method of their use. In particular, the present invention relates to compounds of formula (I).

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• C07F 9/6561 - Composés hétérocycliques, p.ex. contenant du phosphore comme hétéro-atome du cycle contenant des systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un carbocycle ou un système carbocyclique commun, avec ou sans autres hétérocycles non condensés

Abrégé

The present invention relates to nucleic acid cassettes for gene therapy, particularly to nucleic acid cassettes encoding therapeutic proteins in combination with exogenous signal peptides. The invention further relates to viral and non-viral vectors comprising such nucleic acid cassettes, and the use of such nucleic acid cassettes and vectors to increase expression of therapeutic proteins by airway cells.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 14/535 - CSF du type granulocyte; CSF du type granulocyte-macrophage
• C07K 14/78 - Peptides du tissu connectif, p.ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid (CIG)
• C07K 14/81 - Inhibiteurs de protéase
• C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
• C12N 15/86 - Vecteurs viraux

Abrégé

The invention relates to methods for determining if a pea variety or a product derived from that pea variety has improved digestion properties. The invention also relates to methods of improving the digestion property of a pea, as well as method of making such plants.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• A23L 33/21 - Adjonction de substances essentiellement non digestibles, p.ex. de fibres diététiques
• C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
• C12Q 1/6895 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les plantes, les champignons ou les algues
• G01N 33/02 - Nourriture

Abrégé

Disclosed herein is a photoplethysmography (PPG) system for health monitoring. The system comprises a first sensor array configured to collect first PPG data and configured for attachment to a patient at a first sensing site; a second senor array configured to collect second PPG data and configured for attachment to the patient at a second sensing site; and one or more processors configured to receive the first and second PPG data and determine, based on the first and second PPG data and a known distance between the first and second sensing site, a blood pressure value for the patient.

Classes IPC  ?

• A61B 5/021 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins
• A61B 5/024 - Mesure du pouls ou des pulsations cardiaques
• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• A61B 5/01 - Mesure de la température de parties du corps
• A61B 5/0205 - Evaluation simultanée de l'état cardio-vasculaire et de l'état d'autres parties du corps, p.ex. de l'état cardiaque et respiratoire

Abrégé

The present invention relates to chimeric antigen receptor (CAR)-T cells, and particularly, although not exclusively, to anti-CD4 CARs, and to their use in immunotherapy, and for treating, preventing or ameliorating cancer, such as T-cell lymphomas, various microbial infections, such as HIV and TB, and also autoimmune disease. The invention is especially concerned with the use of CAR-engineered mucosal-associated invariant T (MAIT) cells, and to novel methods for stimulating, isolating and expanding highly purified MAIT cells, which can then be engineered into such CAR-MAIT cells. The invention extends to genetic constructs per se, and to their use in generating the CAR-MAIT cells, and to transduced CAR-MAIT cells per se. The invention also extends to various medical uses of the constructs and transduced CAR-MAIT cells, and to pharmaceutical compositions comprising these constructs and CAR-MAIT cells.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
• C07K 14/71 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des régulateurs de croissance
• C07K 14/725 - Récepteurs de lymphocytes-T
• C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 9/64 - Protéinases provenant de tissu animal, p.ex. rennine
• C12N 15/86 - Vecteurs viraux

Abrégé

This invention relates to Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to the expansion of NK cells by increasing the expression of specific transcription factors associated with NK cell production using a new library of compounds.

Classes IPC  ?

• C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
• C12N 5/0789 - Cellules souches; Cellules progénitrices multipotentes
• A61K 31/33 - Composés hétérocycliques

Abrégé

The invention relates to compounds of Formula (I): and related aspects. The invention relates to compounds of Formula (I): and related aspects.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61P 35/00 - Agents anticancéreux
• C07D 487/08 - Systèmes pontés
• C07D 495/04 - Systèmes condensés en ortho

Abrégé

The present invention relates to antibiotic-resistant bacteria, and to the prevention or treatment of infections of drug-resistant pathogens, such as carbapenem-resistant Enterobacteriaceae (CRE) and/or vancomycin-resistant Enterococcus (VRE). In particular, the invention relates to the treatment or prevention of colonisation of CRE and/or VRE in the gastrointestinal (GI) tract, before they cause invasive infections, for example in the blood. The invention provides novel formulations, pharmaceutical compositions and methods of using them to prevent or treat CRE and/or VRE infections or intestinal colonisations thereof.

Classes IPC  ?

• A61K 35/741 - Probiotiques
• A61K 31/215 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques
• A61P 31/04 - Agents antibactériens

Abrégé

An implantable stimulation device is described. The device comprises: signal receiving means for receiving a signal from a heart; and signal delivery means for delivering an output signal to the heart. In response to receiving the signal from the signal receiving means, the implantable stimulation device configured to determine whether the signal is indicative of ventricular tachycardia. Upon positive determination that the signal is indicative of ventricular tachycardia, determine whether the signal is indicative of sustained ventricular tachycardia or spontaneously-terminating ventricular tachycardia. Upon positive determination that the signal is indicative of sustained ventricular tachycardia, send an output signal via the signal delivery means, else if upon positive determination that the signal is indicative of spontaneously-terminating ventricular tachycardia, delay sending the output signal via the signal delivery means.

Classes IPC  ?

• A61N 1/365 - Stimulateurs cardiaques commandés par un paramètre physiologique, p.ex. par le potentiel cardiaque
• A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque

Abrégé

An attachment for use with a device to scan a surface, for example a bony surface, the attachment comprising: a first housing portion configured to releasably secure a device comprising a camera, a second housing portion connected to the first housing portion and having a wall defining an internal region of the second housing portion and an external region of the second housing portion, and a plurality of pins slidably secured to the wall, each of the plurality of pins having a proximal end disposed in the internal region and a distal end disposed in the external region. Upon abutment of the distal end of each of the pins against a surface, the proximal end of each of the pins is configured to translate relative to the wall. When the device is secured to the first housing portion, the proximal ends of the plurality of pins are viewable by the camera.

Classes IPC  ?

• H04N 23/51 - Boîtiers
• A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p.ex. pour le traitement de la luxation ou pour la protection de bords de blessures
• H04M 1/04 - Supports pour microphones ou écouteurs

Abrégé

There is provided methods for diagnosing or aiding diagnosis of pulmonary hypertension (PH), pulmonary arterial hypertension (PAH), and/or chronic thromboembolic pulmonary hypertension (CTEPH) in a subject, determining a subject's risk of developing PH, PAH and/or CTEPH, and/or determining a suitable course of treatment for a subject with PH, PAH and/or CTEPH. The present invention also provides kits comprising means for detecting expression of a panel of microRNAs in a sample.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

A method for recycling dye from a dyed textile, the method comprising providing a textile coloured with a dye; adding the textile to a bath comprising a solution of ionic liquid, thereby causing the dye to strip from the textile and to disperse within said solution.

Classes IPC  ?

• D06P 5/13 - Coloration fugitive ou démontage des colorants
• D06P 1/00 - Procédés généraux de teinture ou d'impression des textiles ou procédés généraux de teinture du cuir, des fourrures ou des substances macromoléculaires solides de toutes formes, classés selon les teintures, les pigments ou les substances auxiliaires u
• D06P 1/66 - Composés contenant des groupes ammonium contenant des groupes ammonium quaternaire
• D06P 1/92 - Procédés généraux de teinture ou d'impression des textiles ou procédés généraux de teinture du cuir, des fourrures ou des substances macromoléculaires solides de toutes formes, classés selon les teintures, les pigments ou les substances auxiliaires u utilisant des colorants dissous dans des solvants organiques ou leurs émulsions aqueuses dans des solvants organiques
• D06P 5/20 - Traitements physiques influant sur la coloration, p.ex. ultrasons ou électricité

Abrégé

Described herein are processes for preparation of flexible fibres coated in 2-dimensional materials. These fibres are suitable for use in electronic devices and may be woven to form electronic textiles.

Classes IPC  ?

• D06M 11/30 - Traitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexes; Un tel traitement combiné avec un traitement mécanique, p.ex. mercerisage avec des oxydes ou des oxyacides d'halogènes ou leurs sels avec des oxydes d'halogènes, des oxyacides d'halogènes ou leurs sels, p.ex. avec des perchlorates
• D06M 11/52 - Traitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexes; Un tel traitement combiné avec un traitement mécanique, p.ex. mercerisage avec du soufre, du sélénium, du tellure, du polonium ou leurs composés par sulfohalogénation avec un mélange de dioxyde de soufre et d'halogènes libres
• D06M 11/58 - Traitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexes; Un tel traitement combiné avec un traitement mécanique, p.ex. mercerisage avec de l'azote ou ses composés, p.ex. avec des nitrures
• D06M 11/74 - Traitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexes; Un tel traitement combiné avec un traitement mécanique, p.ex. mercerisage avec du carbone ou ses composés avec des acides graphitiques ou leurs sels
• D06P 1/673 - Composés inorganiques

Abrégé

An electrode, comprising a monolithic electrochemically active material which is patterned with a plurality of channels.

Classes IPC  ?

• H01M 4/133 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication Électrodes à base de matériau carboné, p.ex. composés d'intercalation du graphite ou CFx
• H01M 4/1393 - Procédés de fabrication d’électrodes à base de matériau carboné, p.ex. composés au graphite d'intercalation ou CFx
• H01M 4/587 - Matériau carboné, p.ex. composés au graphite d'intercalation ou CFx pour insérer ou intercaler des métaux légers
• H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p.ex. batteries à insertion ou intercalation de lithium dans les deux électrodes; Batteries à l'ion lithium
• H01M 4/02 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif

Abrégé

The present invention relates to RNA constructs, and particularly, although not exclusively, to mRNA constructs and saRNA replicons and to nucleic acids and expression vectors encoding such RNA constructs. The invention extends to the use of such RNA constructs in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
• A61P 37/02 - Immunomodulateurs

Abrégé

A lid assembly for a sample tube, for collecting magnetic beads from the sample tube and subsequently releasing said beads, the lid assembly comprising: a closure part including means for removably attaching the closure part to the opening of the sample tube, to close the sample tube, and a bead-collecting platform arranged to locate within or above the opening of the sample tube when the closure part is attached to the sample tube, wherein the bead-collecting platform has a bead-collecting surface on one side, for coming into contact with liquid in the sample tube during use, and a magnet-receiving cavity on the other side, behind the bead-collecting surface; and a magnet-bearing part comprising a magnet, wherein the magnet is removably insertable into the magnet-receiving cavity, towards the bead-collecting surface, such that, when the magnet is present within the magnet-receiving cavity, the magnet is capable of holding magnetic beads against the bead-collecting surface, and when the magnet is not present within the magnet-receiving cavity, the lid assembly is incapable of magnetically holding magnetic beads against the bead-collecting surface. Also provided is a method of using such apparatus to collect magnetic beads from a liquid within a sample tube, and associated kits and accessories.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
• B01L 1/00 - Enceintes; Chambres
• B01L 9/06 - Supports de tubes à essai; Porte-tubes à essai
• B03C 1/28 - Bouchons et jauges magnétiques

Abrégé

A device (1) for use as a physical neural network is described. The device includes a plurality of artificial neurons (2). Each artificial neuron includes a ferromagnetic thin-film nanomagnetic structure (3) having a respective switchable magnetic state. The device is responsive to input data taking the form of a field generated by a control apparatus (5). The input data is for switching one or more of the magnetic states and/or for exerting control over spin-wave dynamics of one or more of the magnetic states. The magnetic states and/or the spin-wave dynamics are readable by one or more sensors (6) to provide output data.

Classes IPC  ?

• G06N 3/044 - Réseaux récurrents, p.ex. réseaux de Hopfield
• G06N 3/045 - Combinaisons de réseaux
• G06N 3/065 - Moyens analogiques
• G06N 3/08 - Méthodes d'apprentissage

Abrégé

The present invention relates to gene therapy agents for the treatment of pulmonary alveolar proteinosis (PAP), particularly autoimmune PAP (aPAP). In particular, the present invention relates to gene therapy vectors which drive transient and/or low-level expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), which provide a therapeutic effect without therapy-associated toxicity. The invention further relates to related products and an animal model of aPAP.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• A61K 38/19 - Cytokines; Lymphokines; Interférons

Abrégé

The invention relates to methods of screening for the presence of proteopathies, to methods of diagnosing proteopathies, to methods of differentially diagnosing proteopathies, to methods of assessing the severity, stage and/or prognosis of proteopathies, and to methods for monitoring the progression of proteopathies. The invention also relates to methods for determining the efficacy of therapeutic interventions for proteopathies.

Classes IPC  ?

• G16B 25/10 - Profilage de l’expression de gènes ou de protéines; Estimation ou normalisation de ratio d’expression
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• G16B 40/20 - Analyse de données supervisée
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique

Abrégé

Laser systems are provided. The laser systems comprise a pump laser source configured to generate pump laser pulses; a first nonlinear medium; and a second nonlinear medium. A cascade of nonlinear processes leads to the generation of optical pulses at different wavelengths. Methods of generating optical pulses are also provided.

Classes IPC  ?

• G02F 1/35 - Optique non linéaire
• H01S 3/00 - Lasers, c. à d. dispositifs utilisant l'émission stimulée de rayonnement électromagnétique dans la gamme de l’infrarouge, du visible ou de l’ultraviolet
• H01S 3/23 - Agencement de plusieurs lasers non prévu dans les groupes , p.ex. agencement en série de deux milieux actifs séparés

Abrégé

A computer-implemented method is disclosed. The method comprises classifying an arterial Doppler ultrasound waveform using the arterial Doppler ultrasound waveform and/or a set of features extracted from the arterial Doppler ultrasound waveform using one or more trained machine learning models to identify whether a peripheral arterial disease condition is present and/or to predict a medical outcome related to peripheral arterial disease. The method comprises, upon identifying the presence of the peripheral arterial disease condition and/or predicting the medical outcome, signalling the presence of the peripheral arterial disease condition and/or the medical outcome.

Classes IPC  ?

• A61B 8/08 - Détection de mouvements ou de changements organiques, p.ex. tumeurs, kystes, gonflements
• A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
• G06N 20/10 - Apprentissage automatique utilisant des méthodes à noyaux, p.ex. séparateurs à vaste marge [SVM]

Abrégé

The present invention provides phagemid vectors and associated phagemid particles for cancer treatment, and in particular, to the use of novel phagemid particles and associated expression systems for the treatment, prevention, amelioration, or management of cancer. In particular, the invention relates to the use of phagemid particles and expression systems for the delivery of transgenes encoding cytokines, for the treatment, prevention, amelioration, or management of cancer. The invention also extends to the use of phagemid particles and expression systems for the delivery of transgenes, and for the combination of such treatment with the use of adoptively transferred T cells, for the treatment, prevention, amelioration, or management of cancer.

Classes IPC  ?

• C07K 14/525 - Facteur de nécrose de tumeurs (TNF)
• C07K 14/54 - Interleukines (IL)
• C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
• C12N 15/86 - Vecteurs viraux

Abrégé

The invention relates to polymeric compositions, nanoparticles and vaccines comprising polymeric compositions. The invention extends to medical uses of the polymeric compositions, nanoparticles and vaccines. The invention further extends to methods of producing the polymeric compositions and nanoparticles.

Classes IPC  ?

• C08L 79/02 - Polyamines
• C07C 323/41 - Y étant un atome d'hydrogène ou de carbone acyclique
• C08G 73/02 - Polyamines

Abrégé

The present invention relates to retroviral vectors modified to improve transgene expression. In particular, the invention relates to retroviral vectors lacking an endogenous Rev response element (RRE) and comprising an intron, particularly a chimeric intron, into which an RRE has been inserted, as well as methods of production and uses thereof.

Classes IPC  ?

• C07K 14/805 - Hémoglobines; Myoglobines
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• C12N 7/02 - Isolement ou purification
• C12N 15/86 - Vecteurs viraux
• C12N 15/867 - Vecteurs rétroviraux

Abrégé

The methods and compositions described herein address the need in the art by providing peptides and polypeptides comprising a growth factor binding domain. In some embodiments, the peptides have an amino acid sequence that is at least 80% identical to one of SEQ ID NOS:1-7, 13-15, 49-50, or 66-70, or a fragment thereof; wherein the peptide is less than 300 amino acids in length.

Classes IPC  ?

• C07K 14/78 - Peptides du tissu connectif, p.ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid (CIG)
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/70 - Bases pour bande, feuille ou filament
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/18 - Facteurs de croissance; Régulateurs de croissance
• A61K 38/39 - Peptides du tissu connectif, p.ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid [CIG]
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61L 27/22 - Polypeptides ou leurs dérivés
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
• C07K 14/475 - Facteurs de croissance; Régulateurs de croissance
• C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
• C07K 14/81 - Inhibiteurs de protéase
• C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

The present invention relates to ADCs comprising a NMT inhibitor conjugated to an antibody via a linker, and related uses.

Classes IPC  ?

• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
• A61P 35/00 - Agents anticancéreux
• C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07D 471/04 - Systèmes condensés en ortho

Abrégé

The present invention relates to compounds of formula (I) and related aspects.

Classes IPC  ?

• A61P 35/00 - Agents anticancéreux

Abrégé

The present disclosure describes a system and method involving a mechanism for a microfluidic pump that leverages alternating adverse and favorable thermocapillary stresses along menisici in a periodically fully-developed internal flow in a microchannel. The system includes interdigitated hot and cold ridges that are asymmetrically disposed relative to each other. The asymmetrical configuration results in different widths of the menisci which drives the microfluidic pump based on the favorable and adverse thermocapillary stresses.

Classes IPC  ?

• F28D 15/02 - Appareils échangeurs de chaleur dans lesquels l'agent intermédiaire de transfert de chaleur en tubes fermés passe dans ou à travers les parois des canalisations dans lesquels l'agent se condense et s'évapore, p.ex. tubes caloporteurs
• F28F 13/16 - Dispositions pour modifier le transfert de chaleur, p.ex. accroissement, diminution en appliquant un champ électrostatique au noyau des sources de potentiel calorifique
• F28F 13/02 - Dispositions pour modifier le transfert de chaleur, p.ex. accroissement, diminution en influençant la couche limite

Abrégé

This invention relates to expanded Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to increasing the number of CD16+ NK cells within expanded NK cell populations without the need for exogenous gene expression.

Classes IPC  ?

• C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK

Abrégé

The invention relates to chimeric antigen receptors (CARs) per se, to CAR constructs, and to T-cell receptor (TCR) beta-chain variable region beta (TCRVβ) CARs. The invention relates to the use of the CARs in immunotherapy, for example in treating, preventing or ameliorating cancer, such as T-cell malignancies, and also conditions caused or implicated by pathogenic T cells, such as autoimmune diseases. The invention is especially concerned with conventional T cells and invariant natural killer T (iNKT) cells expressing anti-TCRVβ CARs and methods for making the same. The invention extends to nucleic acids and vectors encoding the anti-TCRVβ CARs, and to pharmaceutical compositions comprising the constructs and cells, and to medical uses of the compositions, anti-TCRVβ CAR constructs and T cells and iNKT cells expressing anti-TCRVβ CARs.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux

Abrégé

An aircraft arrangement is provided, the aircraft arrangement including a first aircraft component for converting at least one input vibration into an output vibration suitable for driving an energy harvester, and an energy harvester coupled to the first aircraft component and configured to generate electrical energy in response to the output vibration of the first aircraft component, the first aircraft component including a three-dimensional lattice structure including a multiplicity of unit cells, the unit cells including multiple lattice-forming members, the unit cells having a mean greatest dimension of at least 10 nm.

Classes IPC  ?

• H02N 2/18 - Machines électriques en général utilisant l'effet piézo-électrique, l'électrostriction ou la magnétostriction fournissant une sortie électrique à partir d'une entrée mécanique, p.ex. générateurs
• B64D 41/00 - Installations génératrices de puissance pour servitudes auxiliaires

Abrégé

An aspect of the disclosure provides an apparatus comprising: an electromagnetic resonator configured to support an oscillating electromagnetic field in a sample; a cold load having a noise temperature lower than the noise temperature of the electromagnetic resonator; a coupler controllable to provide: a first coupling between the electromagnetic resonator and the cold load to reduce the noise temperature of the electromagnetic resonator; a second coupling, different from the first coupling, to the electromagnetic resonator for sensing an electromagnetic field associated with the sample.

Classes IPC  ?

• G01R 33/36 - Systèmes d'excitation ou de détection, p.ex. utilisant des signaux radiofréquence - Détails électriques, p.ex. adaptations ou couplage de la bobine au récepteur

Abrégé

The invention generally relates to products for use in the treatment and/or prevention of tissue fibrosis, and to methods of identifying agents which inhibit tissue fibrosis. More specifically, the invention relates to agents that inhibit succinate dehydrogenase, and monocyte-recruited macrophage populations, for use in the treatment and/or prevention of tissue fibrosis.

Classes IPC  ?

• A61K 31/194 - Acides carboxyliques, p.ex. acide valproïque ayant plusieurs groupes carboxyle, p.ex. acides succinique, maléique ou phtalique
• A61K 35/15 - Sang; Sang artificiel cellules présentatrices d’antigène, p.ex. cellules dendritiques,
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique

Abrégé

The invention relates to monoclonal antibody production and isolation, and particularly, although not exclusively, to a novel feeder cell line for culturing a monoclonal antibody-producing B cell. The invention also extends to the use of the feeder cell line in culturing a monoclonal antibody-producing B cell, and isolating the B cell from the cell culture media. The invention further extends to methods for culturing and isolating a monoclonal antibody-producing B cell, as well as a method for isolating a monoclonal antibody.

Classes IPC  ?

• C12N 5/0781 - Cellules B; Leurs progéniteurs
• C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux

Abrégé

An optical arrangement for oblique plane microscopy, comprising: an illumination generator arranged to provide abeam of illumination through a first objective lens to illuminate or excite an oblique plane of a sample in use, wherein the first objective lens is also arranged to receive abeam of emitted light from the oblique plane of the sample in use; first and second relay lenses and a second objective lens sequentially arranged to receive the beam of emitted light from the first objective lens and to form, at the focal plane of the second objective lens, an intermediate image having a tilted plane conjugate to that of the oblique plane of the sample; a first mirror located at said focal plane of the second objective lens, arranged to receive and reflect the beam of emitted light; a third relay lens; and an image detector; wherein the second objective lens and the third relay lens are arranged to relay the intermediate image from the first mirror to the image detector; wherein the first minor is also arranged to receive the beam of illumination from the illumination generator and to reflect the beam of illumination through the second objective lens; and wherein the optical arrangement further comprises abeam splitter disposed between the second objective lens and the second relay lens, the beam splitter being configured to: (i) direct the beam of illumination from the second objective lens to the second relay lens, and thence to the first relay lens, the first objective lens and the sample; (ii) direct the beam of emitted light from the second relay lens to the second objective lens, and thence to the first mirror; and (iii) direct the reflected beam of emitted light from the second objective lens to the third relay lens and thence to the image detector. Also provided is a corresponding method of performing oblique plane microscopy.

Classes IPC  ?

• G02B 21/36 - Microscopes aménagés pour la photographie ou la projection
• G02B 21/00 - Microscopes

Abrégé

An apparatus comprising: at least one processor; and at least one memory including computer program code, the at least one memory and computer program code configured to, with the at least one processor, cause the apparatus to: receive a sensor output from a mechanomyography sensor configured to monitor muscle activity of a muscle in a human or animal body; and control, in response to the received sensor output, an electrical stimulus applied by a muscle stimulator to the muscle to modify said muscle activity, wherein the electrical stimulus is applied with an amplitude below the motor threshold of the muscle simultaneously during monitoring of the muscle activity by the mechanomyography sensor.

Classes IPC  ?

• A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
• A61N 1/02 - SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE ÉLECTROTHÉRAPIE; MAGNÉTOTHÉRAPIE; THÉRAPIE PAR RADIATIONS; THÉRAPIE PAR ULTRASONS Électrothérapie; Circuits à cet effet - Parties constitutives

Abrégé

The present application relates to a method of obtaining an optimised transcriptomic signature for identification of a biological condition. The optimised transcriptomic signature being optimised for detection via a particular test platform of a plurality of test platforms, each test platform being associated with at least one requirement. The method comprises receiving transcriptomic data obtained from a first set of subjects, wherein a first subset of subjects in the first set of subjects do have the biological condition, and a second subset of subjects in the first set of subjects do not have the biological condition processing the transcriptomic data to identify a plurality of candidate features, each candidate feature being suitable for use in identifying the biological condition. The method further comprises processing, based on at least one first requirement associated with a first test platform of the plurality of test platforms, the plurality of candidate features. The method further comprises outputting, based on the processing of the plurality of candidate features, the optimised transcriptomic signature for identification of a biological condition being optimised for detection via the first test platform, the optimised transcriptomic signature comprising at least one feature of the plurality of candidate features. The application also relates to a system comprising a memory for storing computer-readable instructions; and one or more processors for executing the computer readable instructions to perform the method.

Classes IPC  ?

• G16B 25/00 - TIC spécialement adaptées à l’hybridation; TIC spécialement adaptées à l’expression de gènes ou de protéines

Abrégé

Disclosed herein is an apparatus for determining a severity of a respiratory condition. The apparatus comprises means for receiving data indicative of an intensity of light detected during a photoplethysmography measurement. The apparatus comprises means for determining an indication of intrathoracic pressure based on the received data. The apparatus further comprises means for determining a severity of a 10 respiratory condition based on the determined indication of intrathoracic pressure. A system comprising the apparatus and a sensor for photoplethysmography measurement is also provided.

Classes IPC  ?

• A61B 5/0295 - Mesure du débit sanguin utilisant la pléthysmographie, c. à d. par mesure des variations du volume d'une partie du corps induites par la circulation du sang qui traverse cette partie, p.ex. pléthysmographie par impédance
• A61B 5/03 - Mesure de la pression des fluides à l'intérieur du corps autre que la pression du sang, p.ex. de la pression cérébrale
• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• A61B 5/0205 - Evaluation simultanée de l'état cardio-vasculaire et de l'état d'autres parties du corps, p.ex. de l'état cardiaque et respiratoire
• A61B 5/08 - Dispositifs de mesure pour examiner les organes respiratoires
• A61B 5/085 - Mesure de l'impédance des organes respiratoires ou de l'élasticité pulmonaire

Abrégé

The present invention relates to a process for preparing a porous metal fibre mat comprising providing a slurry comprising particles selected from metal particles, metal compound particles, or combinations thereof, and a polymer carrier in a solvent, electrospinning the slurry to fabricate a composite fibre mat, and heating the composite fibre mat to produce the porous metal fibre mat. The present invention also relates to a porous metal fibre mat having a specific surface area of at least 500 cm-1 and a thickness of at least 0.05 mm, and uses of the same as an electrode, a catalyst, a catalyst support, or a filtration material.

Classes IPC  ?

• C22C 49/08 - Métaux du groupe du fer
• B22F 1/054 - Particules de taille nanométrique
• B22F 9/20 - Fabrication des poudres métalliques ou de leurs suspensions; Appareils ou dispositifs spécialement adaptés à cet effet par un procédé chimique avec réduction de mélanges métalliques à partir de mélanges métalliques solides
• B22F 3/00 - Fabrication de pièces ou d'objets à partir de poudres métalliques, caractérisée par le mode de compactage ou de frittage; Appareils spécialement adaptés à cet effet

Abrégé

The use of di-tungsten penta-boride, W2B5, within a neutron shield is disclosed.

Classes IPC  ?

• G21F 1/06 - Céramiques; Verres; Réfractaires
• G21F 1/08 - Métaux; Alliages; Cermets, c. à d. mélanges frittés de céramiques et métaux
• G21B 1/05 - Réacteurs de fusion thermonucléaire avec confinement magnétique ou électrique du plasma

Abrégé

Apparatus are disclosed that are arranged to be entirely subcutaneously-implanted, the apparatus comprising an electrochemical sensor for sensing at least one analyte, and a near-field communication (NFC) interface for percutaneous communication of information sensed by the electrochemical sensor.

Classes IPC  ?

• A61B 5/145 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang
• A61B 5/1473 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p.ex. par des moyens polarographiques invasifs, p.ex. introduits dans le corps par un cathéter

Abrégé

The present invention relates to a method for preparing porous adsorbent particles. The present invention also relates to a porous adsorbent particle and a sampling device containing a plurality of said particles. The present invention also relates to the use of said particle or said sampling device.

Classes IPC  ?

• B01J 20/26 - Composés macromoléculaires synthétiques
• B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
• B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
• B01D 53/02 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p.ex. chromatographie préparatoire en phase gazeuse
• B01J 2/02 - Procédés ou dispositifs pour la granulation de substances, en général; Traitement de matériaux particulaires leur permettant de s'écouler librement, en général, p.ex. en les rendant hydrophobes par division du produit liquide en gouttelettes, p.ex. par pulvérisation, et solidification des gouttelettes
• G10K 15/00 - Acoustique non prévue ailleurs
• G10K 11/00 - Procédés ou dispositifs pour transmettre, conduire ou diriger le son en général; Procédés ou dispositifs de protection contre le bruit ou les autres ondes acoustiques ou pour amortir ceux-ci, en général

Abrégé

An apparatus for treating benign paroxysmal positional vertigo, BPPV, comprises at least a processing unit and a feedback mechanism. The processing unit is configured to receive data indicative of a manoeuvre carried out by a user and to compare the received data to data indicative of a predefined manoeuvre for treating BPPV, and the feedback mechanism is configured to provide feedback to the user in accordance with the result of the comparison between the received data and the predefined manoeuvre. In some embodiments the feedback may be provided as audio output, for example in the form of intelligible speech descriptive of a similarity and/or a difference between the manoeuvre carried out by the user and the predefined manoeuvre. A corresponding method and computer program for performing the method are also disclosed.

Classes IPC  ?

• G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
• G06F 1/16 - TRAITEMENT ÉLECTRIQUE DE DONNÉES NUMÉRIQUES - Détails non couverts par les groupes et - Détails ou dispositions de structure
• G06F 3/0346 - Dispositifs de pointage déplacés ou positionnés par l'utilisateur; Leurs accessoires avec détection de l’orientation ou du mouvement libre du dispositif dans un espace en trois dimensions [3D], p.ex. souris 3D, dispositifs de pointage à six degrés de liberté [6-DOF] utilisant des capteurs gyroscopiques, accéléromètres ou d’inclinaiso

Abrégé

The invention generally relates to products for use in the treatment and/or prevention of Pulmonary Arterial Hypertension (PAH). More specifically, the invention relates to translocator protein (TSPO) binding members which treat or prevent pulmonary endothelial cell dysfunction, and the use of such TSPO binding members for use in the treatment and/or prevention of PAH [FIG. 1].

Classes IPC  ?

• A61K 31/522 - Purines, p.ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p.ex. hypoxanthine, guanine, acyclovir
• A61P 9/12 - Antihypertenseurs

Abrégé

A method comprising obtaining image data captured by a camera device. The image data represents an observation of at least part of an environment. A camera pose estimate associated with the observation is obtained. Rendered image data is generated based on the camera pose estimate and a model of the environment for generating a three-dimensional representation of the at least part of the environment. The rendered image data is representative of at least one rendered image portion corresponding to the at least part of the environment. The method includes evaluating a loss function based on the image data and the rendered image data, thereby generating a loss. At least the camera pose estimate and the model are jointly optimised based on the loss, thereby generating an update to the camera pose estimate, and an update to the model.

Classes IPC  ?

• G06T 17/00 - Modélisation tridimensionnelle [3D] pour infographie
• G06T 7/50 - Récupération de la profondeur ou de la forme
• G06T 7/70 - Détermination de la position ou de l'orientation des objets ou des caméras
• B25J 9/16 - Commandes à programme

Abrégé

Systems and methods are provided for verifying the transformational robustness of a neural network. Data is obtained representing a trained neural network, a set of algebraic constraints on the output of the network, and a range of inputs to the neural network over which the algebraic constraints are to be verified, such that the data defines a transformational robustness verification problem. A set of complementary constrains on the pre-activation of a node in the network are then determined such that for any input in the range of inputs, at least one of the complementary constraints is satisfied. A plurality of child verification problems are generated based on the transformational robustness verification problem and the set of complementary constraints. For each child verification problem, it is determined whether a counter-example to the child verification problem exists. Based on the determination of whether counter-examples to the child verification problems exist, it is determined whether the neural network is transformationally robust.

Classes IPC  ?

• G06N 3/10 - Interfaces, langages de programmation ou boîtes à outils de développement logiciel, p.ex. pour la simulation de réseaux neuronaux
• G06N 3/048 - Fonctions d’activation

Abrégé

A method comprising obtaining image data captured by a camera device. The image data represents an observation of an environment. A two-dimensional representation of at least part of the environment is obtained using a model of the environment. The method includes evaluating a difference between the two-dimensional representation and at least part of the observation. The at least part of the observation is of the at least part of the environment represented by the two-dimensional representation. Based on the difference, a portion of the image data is selected for optimising the model. The portion of the image data represents a portion of the observation of the environment. The method comprises optimising the model using the portion of the image data.

Classes IPC  ?

• G06T 17/00 - Modélisation tridimensionnelle [3D] pour infographie
• G06T 7/11 - Découpage basé sur les zones
• G06T 7/50 - Récupération de la profondeur ou de la forme
• G06T 7/70 - Détermination de la position ou de l'orientation des objets ou des caméras
• G06V 10/75 - Appariement de motifs d’image ou de vidéo; Mesures de proximité dans les espaces de caractéristiques utilisant l’analyse de contexte; Sélection des dictionnaires

Abrégé

The present invention relates to compounds derivable from the esterification of a fatty alcohol and furoic acid according to Formula (I). The present invention also relates to the use of said compounds as surfactants, compositions comprising said compounds, and the manufacture of said compounds.

Classes IPC  ?

• C07D 307/12 - Radicaux substitués par des atomes d'oxygène
• C07D 307/64 - Atomes de soufre

Abrégé

A method for producing an additive manufacturing feedstock, the method comprising adding a photothermal agent to a construction material to cause the photothermal agent to be in thermally conductive contact with the construction material, whereby to produce the additive manufacturing feedstock, wherein the photothermal agent comprises chemically modified graphene, CMG.

Classes IPC  ?

• B29C 64/165 - Procédés de fabrication additive utilisant une combinaison de matériaux solides et liquides, p.ex. une poudre avec liaison sélective par liant liquide, catalyseur, inhibiteur ou absorbeur d’énergie
• C01B 32/194 - Post-traitement
• B29C 64/314 - Préparation
• B33Y 70/10 - Composites de différents types de matériaux, p.ex. mélanges de céramiques et de polymères ou mélanges de métaux et de biomatériaux

Abrégé

tion of heme oxygenase 1 (HO-1), in particular porphyrin, chlorin, bacteriochlorin or isobacteriochlorin compounds of formula I as defined herein having a tetrapyrrole or reduced tetrapyrrole backbone and a fluorophore. Such compounds can be used in the detection of HO-1 in vivo, ex vivo and in vitro, and can also be used in methods of diagnosis and as research reagents. tion of heme oxygenase 1 (HO-1), in particular porphyrin, chlorin, bacteriochlorin or isobacteriochlorin compounds of formula I as defined herein having a tetrapyrrole or reduced tetrapyrrole backbone and a fluorophore. Such compounds can be used in the detection of HO-1 in vivo, ex vivo and in vitro, and can also be used in methods of diagnosis and as research reagents.

Classes IPC  ?

• C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
• A61K 49/00 - Préparations pour examen in vivo

Abrégé

Apparatus for discriminating between tumour tissue and non-tumorous tissue in real-time, the apparatus comprising: a handheld bioimpedance probe having an elongate body and at least four stimulator electrodes mounted on a distal end of the elongate body, the electrodes being arranged to be held against a region of tissue in use; a current source configured to generate a stimulation current; a voltage sensor; a multiplexer coupled between the current source, the voltage sensor and the stimulator electrodes and configured to changeably switch between a plurality of switching configurations, wherein, in each switching configuration, a first two of the electrodes are connected to the current source, and a second two of the electrodes are connected to the voltage sensor, the electrodes that constitute the first two electrodes and the electrodes that constitute the second two electrodes changing from one switching configuration to the next; and processor-controlled circuitry configured to: control the switching configuration of the multiplexer; control the generation of the stimulation current by the current source and the application of the stimulation current to the first two electrodes of each switching configuration, such that, in use, the stimulation current flows through the tissue between the first two electrodes; control the measurement, by the voltage sensor, of the voltage between the second two electrodes of each switching configuration, across the tissue in use; determine, based on the applied current and the measured voltage for each switching configuration, a measure of relative impedance of the tissue for each switching configuration; and supply such impedance measurements as output data to a data analyser to enable real-time discrimination of the tissue to be performed, based on the impedance measurements. A handheld surgical tool is also provided, comprising an elongate body and an adjustable handle member that is pivotally coupled to the elongate body.

Classes IPC  ?

• A61B 5/0538 - Mesure de l'impédance ou de la conductivité électrique d'une partie du corps invasive, p.ex. en utilisant un cathéter
• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus

Abrégé

A computer implemented method for updating a scene representation model is disclosed. The method comprises obtaining a scene representation model representing a scene having one or more objects, the scene representation model being configured to predict a value of a physical property of one or more of the objects; obtaining a value of the physical property of at least one of the objects, the obtained value being derived from a physical contact of a robot with the at least one object; and updating the scene representation model based on the obtained value. An apparatus is also disclosed.

Classes IPC  ?

• B25J 9/16 - Commandes à programme
• G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
• B25J 13/08 - Commandes pour manipulateurs au moyens de dispositifs sensibles, p.ex. à la vue ou au toucher

Abrégé

A method of determining an arrangement for objects comprises obtaining first data representing a first arrangement of first objects in a scene; inputting the obtained first data into a trained machine learning model to determine a first cost value for the first arrangement. The first cost value is indicative of an extent to which the first arrangement differs from an optimum arrangement of the first objects according to a cost function that the machine learning model has been trained to provide. The method comprises determining a second arrangement for the first objects based on the first cost value.

Classes IPC  ?

• G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
• G06V 10/426 - Représentations graphiques

Abrégé

The invention relates to a catheter for obtaining a sample of mucosal lining fluid from a precise airway or gastrointestinal location in a patient. The catheter comprises a sampling tube and a sampling head, which is in fluid connection with the sampling tube and which has a permeable material in an interior cavity. The sampling head is closed by an exterior wall in which there are a plurality of small apertures such that fluid enters the catheter when the interior pressure is reduced. The catheter can deploy directly through the mouth or nose or via an instrument such as an endoscope, laryngoscope or tracheal tube.

Classes IPC  ?

• A61B 10/00 - Autres méthodes ou instruments pour le diagnostic, p.ex. pour le diagnostic de vaccination; Détermination du sexe; Détermination de la période d'ovulation; Instruments pour gratter la gorge

Abrégé

The present application relates to a computer-implemented systems and methods for protein interaction design using surface fingerprints. The method comprises predicting at least one target interface site with high binding propensity, wherein, optionally, the step of predicting at least one target buried interface site comprises generating at least one surface fingerprint associated with a protein interaction based on at least one protein interface, wherein the at least one surface fingerprint preferably embeds geometric and/or chemical features of molecular surfaces, identifying at least one binding seed that displays required features to engage the target site, and performing a binding seed transplantation to protein scaffolds to confer stability and additional contacts on the designed interface.

Classes IPC  ?

• G16B 15/30 - Ciblage de médicament à l’aide de données structurelles; Prévision d’amarrage ou de liaison moléculaire
• G16B 20/30 - Détection de sites de liaison ou de motifs
• G16B 40/20 - Analyse de données supervisée